UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1402-3
Program Prior Authorization/Notification
Medication Sotyktu™ (deucravacitinib)
P&T Approval Date 1/2023, 7/2023, 7/2024
Effective Date 9/1/2024
1. Background:
Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with
moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Limitations of Use:
Not recommended for use in combination with other potent immunosuppressants.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Sotyktu will be approved based on both of the following criteria:
(1) Diagnosis of moderate-to-severe plaque psoriasis
-AND-
(2) Patient is not receiving Sotyktu in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx
(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya
(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Sotyktu will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Sotyktu therapy
-AND-
(2) Patient is not receiving Sotyktu in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
© 2024 UnitedHealthcare Services, Inc.
1
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx
(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya
(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Medical Necessity may be in place.
4. Reference:
1. Sotyktu [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022
Program Prior Authorization/Notification - Sotyktu (deucravacitinib)
Change Control
1/2023 New program
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
7/2024 Annual review. No changes.
© 2024 UnitedHealthcare Services, Inc.
2